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bstract
The interest in food toxicology is evident by the dependency of humankind on nutrition by virtue of their heterotrophic metabolism. By means
f modern biochemistry, molecular and cell biology, computer science, bioinformatics as well as high-throughput and high-content screening
echnologies it has been possible to identify adverse effects and characterize potential toxicants in food. The mechanisms of toxicant actions are
ultifactorial but many toxic effects converge on the generation of oxidative stress and chronic inflammation resulting in cell death, aging and
egenerative diseases. Integration of food toxicology data obtained throughout biochemical and cell-based in vitro, animal in vivo and human clinical
ettings has enabled the establishment of alternative, highly predictable in silico models. These systems utilize a combination of complex in vitro
ell-based models with computer-based algorithms. A decrease of rodent animal testing with its limitations of high costs, low throughput readouts,
nconsistent responses, ethical issues and concerns of extrapolability to humans have led to an increased use of these but also alternative lower
ierarchy surrogate animal models (e.g. Drosophila melanogaster; Caenorhabditis elegans or Danio rerio) and efforts to integrate organotypic
ystems and stem cell-based assays. Despite those achievements, there are numerous challenges in various disciplines of food toxicology.
2016 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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. Overview
The history of food toxicity might have started as early as
ippocrates made the statement “Let food be thy medicine
nd medicine thy food” which presaged the modern science
y over two millennia ago. With the development of modern
iochemistry, molecular biology, cell culture techniques, com-
uter science and bioinformatics, it has been possible to identify
nd characterize potential toxicants in food [1–7]. Mechanistic
nsights gained by toxicity assessment of food using different
odels ranging from in vitro biochemical, cell-based in vitro,
nimal in vivo to clinical settings have led to a better food safety.∗ Correspondence to: Department of Science (Biology), City University of
ew York, BMCC, 199 Chambers Street, New York, NY 10007, United States.
el.: +1 212 2201305; fax: +1 212 7487471.
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he growing interest in this area is reflected by a stunning 6280
ublications in PubMed as of February 2016 when combining
food, toxicity, review” in searches and the exploding numbers
f around 200 reviews per year on these topics starting from
002 (Fig. 1).
There are two different related areas in the measurement of
oxicants and toxicity in food: (1) actual measurements of the
ffects of toxicants in different models ranging from in vitro
iochemical systems, cell-based in vitro systems, animal in vivo
odels to clinical settings analyzing systemic or organ-specific
oxicity and (2) assessment and/or predictions of potential tox-
cants in food. These two are interrelated since the mechanistic
nowledge gained by the actual assessment of the effects of tox-
cants can lead to the identification of other potential toxicants
n food. The majority of assessment systems for food toxicology
ere developed in the field of pharmacology [5,6,8,9]. Pharma-
ology and nutritional science share common roots since many
f the world’s most commonly used drugs are derived from
atural products as illustrated by the term “nutraceutical” [10].
The mechanisms of toxicant effects are multifactorial inter-
cting intrinsically and extrinsically with key molecules which
lsevier B.V. All rights reserved.
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lay major roles in cell integrity, metabolism, signaling path-
ays, gene expression and translation. For a variety of toxicants
heir effects appear to converge on the generation of electrophilic
pecies (ES) leading to oxidative stress and chronic inflamma-
ion [11–15]. Oxidative reactions induced by toxicants lead to an
ccumulation of damaged macromolecules thus harming cells,
issues and organs. Therefore, toxicants may play central roles
n cell death, chronic inflammation, aging and degenerative dis-
ases such as Alzheimers, Parkinsons and Huntingtons diseases,
s well as multiple sclerosis, myocardial infarction, arterioscle-
osis, diabetes, rheumatoid arthritis, sterility, cataracts and many
thers [13,14,16–23].
For in vitro assessment a variety of biochemical systems
ave been developed to analyze damaging effects on integrity or
ctivity of key biomolecules. Such molecules are important in
ell integrity, metabolism, signaling pathways, as well as gene
xpression and translation. The list of affected molecules is
xtensive and includes enzymes, receptors, membrane lipids,
ucleic acids and/or or factors involved in gene expression
3–6,24–29]. On cellular level, a variety of viability assays are
outinely used to quantify effects of potential food toxicants
or extrapolation of range of dosages used for maximal toler-
ted concentrations for in vivo animal models and also clinical
ettings [3–6,30–32]. For more mechanistic insights, several
ell-based in vitro systems were developed in combination
ith targeted in vitro analyses which focus on cell-specific key
nzymes and receptor-dependent pathways. In vivo rodent mod-
ls still appear to be the gold standard for toxicity assessment
ut there are limitations of such traditional testing such as high
osts, low throughput readouts, inconsistent responses, ethical
ssues and concerns of extrapolability to humans [2,5,6,8]. Con-
equently, new strategies have been developed and the paradigm
n toxicology has switched from the traditional apical endpoint
pproach as determined in animal models to a mechanism-based
pproach by in silico methods [6,7,29,33,34].
In silico screening systems, a combination of focusedn vitro cell-based models and computer based algorithms
mploy a variety of different high-throughput and high-
ontent screening technologies. Cell-specific biomarkers on
c
sruary 2016 when combining “food, toxicity, review” in search.
ene, protein or metabolite levels can be measured by
oxicogenomics, toxicoproteonomics or toxicometabonomics,
espectively [6,27,35–40]. The integration of food toxicology
ata obtained via in vitro biochemical, cell-based, in vivo animal
odels and in silico systems have led to a mechanistic knowl-
dge of systemic or organ-specific toxicity in humans and the
dentification and use of specific surrogate biomarkers in clinical
ettings.
Although complex in vitro cell culture systems integrated
ith in silico systems provide unique mechanistic insights into
n vivo toxicology more relevant to humans, they will never
ompletely model the higher level complexity of cross-talk
hroughout different pathways present in an intact organ-
sm [1,2,4–6,8,41]. Another refinement in toxicity assessment
s the installation of alternative lower hierarchy surrogate
nimal models such as zebrafish (Danio rerio), fruit flies
Drosophila melanogaster) or nematodes (Caenorhabditis ele-
ans). These models offer an advantage in terms of ethical
oncerns, high throughput and genetic manipulation over tradi-
ional rodent models [4–6,42,43]. The value of using alternative
ub-mammalian vertebrate and invertebrate models became evi-
ent by the surprising discovery of the high degree of homology
f genes between humans and zebrafish, fruit flies or nematodes
5,43–49].
Overall, the achievements in food toxicology have signifi-
antly improved the prediction rate of drug and food safety in
imensions as unimagined only a decade ago [4–6,8,50–52].
he deeper understanding of the molecular mode of action
n key targets of biological pathways have enhanced the pre-
ictivity and robustness of in vitro cell-based toxicity models
nd thus led to the improvement of food safety. Moreover,
lthough in early development, stem cell-based screening or
hree-dimensional organotypic models will further increase the
redictivity of acute toxicity and help to answer fundamental
iological questions and/or enable testing of novel therapeutic
pproaches [6,7,53–57].Despite those achievements, at present there are still huge
hallenges to increase the rate of predictivity in various areas
uch as reproductive and developmental toxicity, neurotoxicity,
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enotoxicity, carcinogenicity, immunotoxicity, food allergy, and
ndocrine disruption [4–6,8,27,58–60].
. Molecular effects of toxicants
Although the mechanisms leading to toxic effects in humans
re multifactorial the majority of toxic effects appear to con-
erge on the generation of free radicals. Different electrophilic
pecies (ES) such as reactive oxygen species (ROS) or reac-
ive nitrogen species (RNS) are capable of oxidizing virtually
ll biomolecules. Whereas a variety of toxicants generate ES
irectly, others induce a secondary response leading indirectly
o generation of ES by immunocompetent leukocytes which
lay a key role in the inflammatory cascade [14,15,61]. ES are
lso involved in the modulation of gene expression by inter-
ering with transcription factors and/or DNA which can lead
o mutations and carcinogenesis. The accumulation of damage
o membrane lipids, cellular proteins, carbohydrates as well as
ucleic acids harm the functioning of cells, tissues and organs
11–15,62,63]. These and other observations strengthen the
ypothesis that toxicants leading to oxidative stress and chronic
nflammation play central roles in cell death, aging and degen-
rative diseases [13,14,16–23].
ROS comprise differently reduced oxygen species such as
he superoxide anion radical (•O2−), hydrogen peroxide (H2O2)
nd the highly reactive hydroxyl radical (•OH) [12,13,63–65].
ismutation of these radicals leads to hydrogen peroxide as
fairly stable ROS member. Heavy metals (iron, but also
opper, chromium or vanadium), as an important group of
oxicants, can generate the highly toxic hydroxyl radical by
ay of the Fenton reaction (H2O2 + Fe2+ → •OH + OH− + Fe3+)
12,13,63,66]. Therefore, the amount of hydroxyl radicals
ormed in a cell depends on endogenous ROS generation, but
lso on the amounts of reduced metal ions for the Fenton reaction
o occur [66,67]. The other highly reactive group of molecules
onsists of reactive nitrogen species (RNS). The signal molecule
itric oxide (NO) exists as NO+, NO• and NO– while the per-
xynitrite ion (ONOO−) is generated by the reaction of NO with
he superoxide anion radical [62,63,68].
The oxidation of lipids, proteins, nucleic acids and carbo-
ydrates generate a variety of damaging breakdown products
hich thus can lead to the onset of many degenerative dis-
ases [11–15,62,63,69]. Lipid peroxidation of cell structures
ontaining lipids can lead to the generation of different toxic
roducts, including alcohols, ketones, alkanes, aldehydes and
thers which have the potential to contribute to cell damage,
ecrosis or apoptosis [26,63,70–72]. For proteins thiolgroups of
ysteine residues are the most sensitive targets of ES. Redox-
ependent modifications of intra- and intermolecular disulfide
onds can lead to structural/functional changes and protein
ggregation [12,24,62,73–76]. Altogether these ROS-induced
amages may cause malfunctioning enzymes, transporters,
ignal transducers or structural proteins. Nucleic acids are del-
cate targets of ES leading to mutations. Damage of nucleic
cids by ES may result in single and double strand breaks,
NA–DNA, DNA–protein, DNA–lipid adducts or numer-
us base modifications such as 8-hydroxy-deoxyguaonosine,
d
b
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-hydroxylmethyluracil, 8-hydroxydeoxyadenine and thym-
nglycol [12,19,24,77–80]. Mitochondrial DNA (mtDNA) is
articularly susceptible to oxidative damage because of the
bsence of associated histones, an incomplete mitochondrial
NA repair system and the generation of free radicals through
lectron leakage from the respiratory chain [78–80]. Interest-
ngly, carbohydrate oxidation may also be involved in DNA
amage, as oxidation and fragmentation of deoxyribose frag-
ents produced from DNA by free-radical attack are believed
o play a major role in mutations by blocking the action of DNA
olymerase and DNA ligase [19,27,58,81].
. In vitro biochemical assessment of toxicity
Several in vitro biochemical assessment systems are focused
ither on the measurements of primary or secondary prod-
cts derived from oxidized lipids, proteins, nucleic acids and
arbohydrates or the integrity or activity of a variety of
ey biomolecules which play major roles in cell integrity,
etabolism, signaling pathways, gene expression and transla-
ion [3,11–15,62,63]. Testing whether a chemical can modulate
he activity of particular enzyme or binding affinities to a partic-
lar receptor or other biomolecule is the most direct way to gain
echanistic insights into action at the molecular level. There are
ifferent biochemical in vitro assays which analyze the integrity
r mutation of DNA and RNA, membrane lipids, as well as the
inding and activity of various receptors, enzymes involved in
ignaling transduction, drug or neurotransmitter metabolism and
any others [3–6,24,25,27–29]. The risk assessment of genotox-
city by DNA-reactive toxicants in food is of particular interest
y virtue of the close correlation with carcinogenesis [24,82,83].
o measure the potential for genotoxic activity of food com-
ounds which might lead to mutations traditionally the Ames
acterial reverse mutation test is used [84]. The Ames test is
ased on the growth of several histidine dependent Salmonella
trains carrying different mutations in various genes of the his-
idine operon [6,27,85]. Other methods measuring genotoxic
otential in cell-based systems are discussed below.
A variety of enzyme and receptor-binding assays have
een developed to examine specific mechanisms of action
t the molecular level of different receptors (e.g. ion chan-
els, G-protein coupled receptors, tyrosine kinases, nuclear
eceptors), signaling transduction enzymes (kinases, proteases,
hosphatases, phosphodiesterases), and enzymes metabolizing
rugs (e.g. cytochrome P450 monooxygenases) or neurotrans-
itters (e.g. acetylcholinesterase). As in vitro prescreening tools
he human ether-a-go-go-related gene (hERG) potassium ion
hannel [86–88] or acetylcholinesterase activity assay [89,90]
re routinely used for a global assessment of cardiotoxicity
r neurotoxicity, respectively. Other assays monitor the poten-
ial effects of toxicants which interfere with anti-inflammatory
rugs. These may utilize a high-throughput screening for micro-
omal prostaglandin E synthase activity [91].Xenobiotic metabolism is a commonly encountered problem
uring development of new drug candidates thus applica-
le also for potential toxicants in food [4,9,25,28,34,92].
y far the most important class of metabolic enzymes are
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ytochrome P450 (CYPs) monooxygenase drug metaboliz-
ng phase I enzymes but there are several other classes
f biotransformation enzymes including uridine diphosphate
lucuronosyltransferases (UGTs), glutathione S-transferases
GSTs), N-acetyltransferases (NATs), sulfotransferases (SATs)
nd methyltransferases (MTs) which are referred to phase
I enzymes [25,28,93–95]. The majority of inhibition studies
re using fluorescent or luminescent substrates and recombi-
ant CYPs and UGTs but also various kinases. They employ
igh-throughput formats which involve protein-based microar-
ays [25,94–98]. Other approaches use recombinant CYP450s
etabolizing enzyme toxicology assay chips (MetaChips)
hich assess the toxicity of the generated metabolites by cou-
ling with cell-based screening which thus enable a cell-specific
creening [25,99]. The abundance of in vitro biochemical testing
latforms for CYP450 enzymes is understandable since in vivo
he liver is dependent on these enzymes for detoxification of
enobiotics. Many hepatoma-derived HepG2 cell lines used for
epatotoxicity screening lack functional expression of almost
ll the relevant human xenobiotic metabolizing enzymes in this
amily [28,92,100].
Lipid peroxidation characterized by radical chain reactions
ith the production of a variety of breakdown products fre-
uently serves as marker for oxidative stress and inflammation in
ifferent biochemical in vitro assays [26,63,66,70–72]. Detec-
ion of generated aldehydes, particularly malondialdehyde, is
sed by the thiobarbituric acid test to determine the degree of
ipid peroxidation; these are designated as “thiobarbituric reac-
ive substances” (TBARS) [101]. Because of its sensitivity and
implicity this method is considered as a first global measure
f lipid peroxidation in a variety of chemical as well as bio-
ogical material [26,102]. Other reliable and stable indicators
f oxidative stress include F2-isoprostanes which are generated
uring lipid peroxidation [103,104]. Tert-butyl hydroperoxide
nitiated chemiluminescence is another method which has been
uccessfully utilized to detect oxidative damage associated to
xperimental or pathological situations in subcellular fractions,
issue homogenates, or different organs [105,106].
. Cell-based in vitro assessment of toxicity
The use of cellular models provides a much higher level of
omplexity than simple biochemical assays. A huge number of
uman cell lines are available and a variety of different cell-based
n vitro assays have been developed for screening of food toxi-
ants [3–6,30–32,41]. Usually two basic approaches are applied:
1) a universal screening approach using one or a few cell lines
o assess cell viability and (2) a target-organ-based approach,
sing a panel of different cell types with more specialized func-
ions, such as representative cell lines from different organs such
s liver, heart, kidney lung, brain or others.
.1. Viability assaysFor general assessment of cytotoxicity an indirect measure of
ell viability is usually performed and several cellular bioassays
re routinely used integrating different cytotoxicity endpoints
s
t
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uch as membrane leakage or cellular activity [6,30,31].
hereas the trypan blue, propidium iodide, crystal violet, or
actate dehydrogenase assays are analyzing membrane integrity
ased on exclusion, other viability assays such as the neutral
ed, alamar blue or MTT assay are metabolic measures of cel-
ular activity. Inhibitory concentrations (IC values) obtained by
iability assays are then used for initial dose selection in test-
ng on animals and humans [3,5,30–32]. Inhibitory effects on
ell viability as a measure of cytotoxicity due to necrosis, apo-
tosis or autophagy can be further discriminated by the use of
ssay systems using a variety of specific multiplexed panels
30,31,69].
A prominent and reproducible method to analyze cell via-
ility is the trypan blue exclusion method based on the ratio
f stained versus unstained cells in a sample as a reflection
f membrane damage [107]. Usually, the method is performed
y cell counting but, an elegant quantitative measure of trypan
lue staining has been introduced [108]. Similiar to the trypan
lue exclusion assay, the crystal violet assay is based on the
rowth rate reduction reflected by stained cells through reac-
ion of crystal violet with negatively charged cell components
uch as nucleic acids or peptidoglycans [109,110]. In addition
o the measurement of dyes, activity analysis of enzymes is also
n established technique used to determine membrane integrity.
eakage of intracellular enzymes such as lactate dehydrogenase
LDH) or others into the extracellular medium is thus employed
s indicator of cell membrane damage [30,31,111].
Other frequently used viability assays are based on cel-
ular activity such as the neutral red (NR), MTT or alamar
lue assay. Whereas the NR assay determines cell viability by
ndocytic uptake of neutral red into lysosomes of uninjured
ells [112], the MTT viability assay is based on mitochon-
rial activity by conversion of the yellow tetrazolium salt
TT (3,(4,5-dimethylthiazol-2-yl)-2,5,-diphenyl-tetrazolium-
romide) by mitochondrial dehydrogenase activity to form a
lue formazan product [113]. Similiar to the MTT-method the
lamar blue assay is based on redox-reactions converting blue,
xidized resazurin to reduced resorufin which is red and highly
uorescent [114]. It has been reported that the MTT-method
ased on intracellular redox reactions may yield false-positive
esults for certain cell types when treated with different antiox-
dants [115]. Therefore, it appears to be advisable to include
ther viability assays besides the MTT- but also the alamar
lue method for cell-based toxicity screening [116]. Damage of
itochondria is a major contributor to organ toxicity, such as of
he liver, kidney, heart, muscle, and the central nervous system,
nd mitochondrial dysfunction is increasingly implicated in a
rowing list of degenerative diseases [117–119]. Therefore, the
mpact of toxicants on mitochondria is of particular importance
or toxicity assessment [6,118,119].
.2. Genotoxicity, nutrigenomic and immunotoxicity testingDue to the nature of many toxicants to generate electrophilic
pecies it is not surprising that many of them induce oxida-
ion and damage of DNA or RNA thus leading to genotoxicity
24,27,82,83,120]. Since there is a strong correlation between
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enotoxicity and carcinogenicity, one aim of genotoxicity test-
ng is to identify potentially carcinogenic food ingredients
6,27,120]. Additionally, chronic inflammation is widely rec-
gnized as a major underlying contributor to carcinogenesis
s well as various other degenerative conditions including
ardiovascular-, Alzheimer’s disease, arthritis, and diabetes.
herefore, cell-based models have been developed which ana-
yze the impact of food ingredients on inflammation using
utrigenomic screening, a discipline to analyze the influence
f nutritional compounds on gene expression [61,121–123].
For cell-based genotoxic screening, various exploratory
enetic toxicity assays are used to measure chromosomal dam-
ge in eukaryotic cells. Frequently used models are the mouse
ymphoma tk gene mutation assay, the Chinese hamster ovary
CHO) chromosomal aberration assay, the micronucleus clas-
ogenicity assay and the Comet assay [2,6,27]. Interestingly,
here has been a high false positive rate (low specificity) in
enotoxicity testing which might be due to the recent discovery
f non-covalent DNA interaction and interference of toxicants
ith critical DNA metabolizing proteins such as topoisomerase
nd DNA polymerases [27,58,79–81]. The linkage between cell-
ased in vitro, ex vivo and in vivo evaluation is evident by the
icronucleus test used for genotoxic screening of chromosomal
amage in bone marrow polychromatic erythrocytes [6,124].
lso for immunotoxicity there are several ex vivo test mod-
ls available. Functional immunological tests include activity
f macrophages, natural killer cells and the immune responses
f T- and B-cells [2,125,126]. As for other human organ-based
x vivo tissue or organ toxicology studies on heart, brain, lung,
idney or liver there is an advantage with the in vitro to in vivo
omparison/extrapolation.
.3. Complex cellular toxicity assays
For viability, genotoxicity, immunotoxicity or nutrigenomic
esting usually one cell line is employed. Recently, novel, more
omplex in vitro human cell-based systems are being increas-
ngly used to model mammalian tissues in a more holistic
pproach [5,6,29,51]. A variety of parameters such as key
ignaling pathways, gene and protein expression levels, recep-
or activity, cytoskeletal and membrane integrity, energy status,
orphology of cell organelles, cell movement, cell cycle status,
nd cell differentiation can be quantified on single cell level.
omplex human in vitro cell-based models are well suited to
redict the in vivo response by comparison throughout the panel
f different cells by quantitative in vitro to in vivo extrapolation
hus decomposing complex toxicological pathways of particu-
ar organs [4–6,9,25,27,32,34,41,127]. Correlation analysis with
nimal and clinical studies have led to a high predictivity and
obustness of those complex cell-based in vitro models which
o not have issues with interspecies extrapolation [5,7,34,128].
onsequently, high content as well as high-throughput com-
lex cellular in vitro models focusing on organ-specific toxicity
uch as hepatotoxicity [127,129,130], nephrotoxicity [131,132],
eurotoxicity [133–135], cardiotoxicity [59,136], and respira-
ory toxicity [137,138] are routinely used. An even higher level
f complexity is achieved by three-dimensional organotypic
i
b
t
in Wellness 5 (2016) 103–115 107
odels. Although still in its infancy organotypic systems have a
ery high potential for predicting acute toxicity and can be used
o answer fundamental biological questions, and enable test-
ng of novel therapeutic approaches, often using patient-derived
ells [7,53,54].
.4. Stem cell models
Recently, stem cell-based assays are being discussed as
ource for various toxicological applications [6,55–57] thanks
o the Nobel Prize-winning discovery of how to reprogram ordi-
ary somatic cells to behave like embryonic stem cells [139].
uman-induced pluripotent stem cells (iPSCs) allow assays
o consider an individual’s genetic background and potential
pigenetic influences that affect the variability of the toxic-
ty response [56]. By the use of comprehensive profiling via
enomics, proteomics, transcriptomics, and metabolomics stem
ell in vitromodels offer an unprecedented opportunity to test the
ffects of potential food toxicants in a very predictive and per-
onalized manner [6,55–57]. Stem cell-based models are also
f particular interest for toxicity measurements which either
ack extrapolability in rodent models such as for genotoxic-
ty, cardiotoxicity, respiratory toxicity or for different stages of
isorders which largely remain unknown such as neurological
isorders (depression, anxiety, Alzheimer’s and Parkinson’s dis-
ase), autoimmune diseases (multiple sclerosis, type I diabetes,
sthma), systemic infection, cancer and others [8,27,58–60].
lthough in early development, human stem cell models may
urther reduce the usage of animals in safety and risk assessment
tudies and offer the potential to dramatically enhance our under-
tanding and thus prediction of the molecular basis of toxicity
6,55–57].
. In vivo toxicity assessment in animals
While complex cell culture systems can provide unique
nsights into in vivo toxicology, they will never completely
odel the higher level interactions present in an intact organ-
sm [1,2,4–6,8,41,140]. Therefore, the gold standard for toxicity
ssessment has been in vivo toxicology, where a particular
olecule or complex food ingredients are given to animals to
valuate acute, subacute, and chronic effects. A large body of
nformation about their responses have led to the development of
arious specific high-content animal models that may have the
bility to simulate the genetic heterogeneity of the human pop-
lation and evaluate possible reproductive and developmental
oxicity, neurotoxicity, genotoxicity, carcinogenicity, immuno-
oxicity, food allergy, and endocrine disruption [1,2,4–6,8,9].
The majority of animals used are rodents and to derive sta-
istically significant results the numbers of animals needed for
esting are enormous with an estimation of 7000 animals and
ens of millions of dollars for each test compound in the phar-
aceutical industry [141]. Although the numbers of animals
nvolved in food toxicity screening are decreasing, the num-
ers of compounds or food ingredients to be tested as well as
he costs of the current in vivo assessment systems are explod-
ng [2,5–7,41,42,51,142]. Traditional in vivo toxicity testing is
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lso characterized by low-throughput readouts and ethical con-
erns of using such large quantities of animals from animal
rotection groups. Lastly, there are debates on whether the data
s readily translatable to humans due to differences in species
ensitivity but also because of the heterogeneity of the human
opulation as reflected by a steady increase of reports on adverse
vents [8,143]. The high costs, low-throughput readouts, ethi-
al and extrapolability concerns have urged calls for alternative
trategies in toxicity testing methods [5,7,142].
Consequently, the paradigm of the high use of rodent for
n vivo toxicity testing shifted in recent years with an approx-
mate 50% reduction in the number of animals required for
oxicological tests [4–6,144]. This was paralleled by a focused
se of specific animal models due to a better understanding
f mechanisms. For example, the knowledge gained on the
ffects of toxicants on lipids stems from the similarity of lipid
etabolism between mini pigs and humans, whereas the rat
ppears to be an unsuitable model for the study of cholesterol
evels [2]. Higher specificity was also achieved by the use of new
enetically diverse in vivo high-content models simulating the
enetic heterogeneity of humans or transgenic animals modeling
ommon diseases and/or genetic polymorphisms considering
pecific groups within the general population that may be
t particular risk following exposure to a food component
2,6,7,42,51].
In addition to enhancing the specificity of traditional animal
odels, the value of using alternative sub-mammalian vertebrate
nd invertebrate models became evident by the significant dis-
overies of homologous genes related to development, immune
esponse, cancer or related pathways in humans [5,43–49].
ajorly three test platforms of model organisms are adapted
o high-throughput screening. These include the fruit fly D.
elanogaster; the nematode C. elegans and the zebrafish D.
erio. The use of these but also other alternative lower hierar-
hy surrogate animal models offers an advantage in the ease of
thical concerns in terms of high throughput and genetic manip-
lation over traditional rodent models [4–6,42,43]. However, as
ith all animal models, alternative in vivo models also have the
aveat of extrapolation issues related to species differences.
The use of the fruit fly D. melanogaster has been recognized
s a model organism in studies of genetics and developmen-
al biology for over 100 years [145]. The genome is fully
equenced showing that nearly 75% of human disease-causing
enes have a functional homolog in D.melanogaster [43,45,47].
xtensive genetic manipulation of the fruit fly via knockout
r knockdown by RNAi is available for modifying fruit fly
enetics [43,45,146]. Interestingly, fruit flies have the poten-
ial to be used for chemical-toxicity screens particularly for
eurotoxicity due to the high degree of orthologs associated
o genes known to be involved in neurodegenerative diseases
43,47,147–149]. The nematode C. elegans is easily cultured
n the lab and widely used for biomedical research. More than
0% of human genes have functional orthologs in C. elegans
nd all 959 somatic cells of the worms have been characterized
ith respect to lineage [46,150,151]. As for D. melanogaster,
variety of molecular tools provide the availability of a large
umber of transgenic strains suited for a differential toxicity
d
e
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creening by high-throughput genomic studies [46,150–152].
ince C. elegans is capable of rudimentary learning and many
eurotransmitters are well conserved it is also well suited for
eurotoxicity testing [151,153,154]. More recently, the zebrafish
. rerio has been used as a vertebrate model organism for a wide
ariety of research including drug discovery and toxicology. The
ncreased usage of zebrafish as in vivo model system reflects the
triking similiar toxicity profile between humans and zebrafish
ue to substantial physiological, anatomic, and genetic homol-
gy [44,49,155,156]. The zebrafish model is also amenable to
ene manipulation, is low in cost, has a short generation time,
nd is particular well suited for high-throughput screening as
ell as microarray and proteomic studies [48,157,158]. Since
ebrafish larvae are transparent they are ideal for studies on
rgan morphology by in vivo imaging techniques in addition
o more detailed studies by immunohistochemistry or in situ
ybridization [49,155,158].
. Toxicity assessment in humans
Toxicity assessment in humans involves different fields such
s clinical, forensic, environmental, and regulatory toxicology.
systemic determination of toxicants in body tissues is usu-
lly obtained by biopsy or by analyzing body fluids such as
lood and urine. Clinical toxicology is mainly based on analyz-
ng genotoxicity, neurotoxicity, cardiotoxicity, hepatotoxicity,
ephrotoxicity, carcinogenicity, immunotoxicity, food allergy,
nd/or endocrine disruption as they affect a variety of disorders
13,14,16–23].
A great deal of knowledge on toxicity in humans has been
btained by post mortem molecular and anatomic analysis of
ells, tissues and organs [159,160]. Forensic toxicology is very
elated to toxicologic pathology but focusing more on the appli-
ation to the purposes of the law [160,161]. The discipline
f environmental toxicology is related to studies of various
hemical, biological and physical agents which are harmful
o humans, whereas regulatory toxicology is concerned with
isk assessment of food and potential toxicants [51,162]. By
irtue of advances in nanotechnology and its application in food
ndustry, the newly created discipline of nanotoxicology investi-
ates safety or potential hazards of nanoparticles [52,163–165].
nother dimension refers to genetically modified organisms
GMO) or genetically modified food (GMF) as potential source
f toxicity [52,166,167]. All the different disciplines of toxic-
ty assessment in humans are not mutually exclusive but rather
ighly interconnected. The goal is to identify and understand
he molecular mechanisms of toxicants causing adverse effects
n order to ultimately prevent their intake thus increasing food
afety [52,168].
A major tool in clinical toxicology is the use of surrogate
iomarker molecules as specific indicators of organ and tis-
ue damage. As a consequence of the rapid development in
iotechnology an increase of specificity as well as sensitivity of
etection levels has led to a better predictivity of those biomark-
rs. Toxicological assessment of organ and tissue damage can be
rouped in two basic types of biomarkers which indicate differ-
nt adverse biological effects: (1) biomarkers assessing function
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Table 1
Organ-specific biomarkers. Different biomarkers indicating organ-specific dam-
age are listed. For reference see: [1,3–6,8,9,23,52,59,86,130–136,168–173,
191–194].
Organ Biomarker
Liver Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)
Alkaline phosphatase (ALP)
Glutamate dehydrogenase (GLDH)
Glutathione S-transferase (GST)
Kidney Kidney injury molecule (KIM)
Beta-2-microglobulin (B2M)
Neutrophil gelatinase-associated lipocalin (NGAL)
Glutathione S-transferase (GST)
Cystatin C
Brain Neuron-specific enolase (NSE)
Neuregulin-1 (NRG-1)
Glial fibrilary acidic protein (GFAP)
Myelin basic protein (MBP)
S100B
Heart Creatine kinase (CK)
Myoglobin
Troponins (C, I, T)
C-reactive protein (CRP)
Cardiac troponin T and I
Cardiac natriuretic peptide (CNP)
Ischemia-modified albumin (IMA)
Vascular Vascular endothelial growth factor (VEGF)
Caveolin-1
GRO/CINC-1
Thrombospondin-1 (TSP-1)
Alpha-smooth muscle actin (SMA)
Calponin
Transgelin
Muscle Creatine kinase (CK)
Myoglobin
a
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Table 2
Inducible biomarkers. Different damage-responsive biomarkers are listed.
For reference see: [1,3–6,8,9,11–16,22,28,39,52,61–67,70,76–80,91,170,171,
173,195–197].
Group of
inducible
biomarkers
Biomarker
Antioxidant
enzymes
Superoxide dismutases (SOD-1, SOD-2)
Catalase (CAT)
Glutathione peroxidases (GPx1 -8)
Glutathione reductase (GR)
Glutathione S-transferases (GSTs)
Heme oxygenases (HO-1, HO-2)
Antioxidants Glutathione (GSH)
Nicotinamide adenine dinucleotide (NADH)
Ubiquinone
Cysteine
N-acetyl-cysteine
Lipoic acid
Uric acid
Melatonin
Bilirubin
Metal-chelating
proteins
Transferrin
Ferritin
Ceruloplasmin
Metallothioneins (MT-I, MT-II)
Repair enzymes DNA helicases
O-methyltransferases (OMTs)
Formamidopyrimidine-DNA glycolyase
protein (Fpg protein)
Poly (ADP-ribose) polymerase-1 (PARP-1)
Uracil-DNA glycolyse (UDG)
Ultraviolet radiation proteins (Uvr proteins)
Heat shock protein-27 (Hsp27)
Heat shock protein-70 (Hsp70)
Heat shock protein-90 (Hsp90)
Transcription
factors
Protein 53 (p53)
Nuclear factor kappa B (NFB)
Growth arrest and DNA-damage-inducible
gene 153 (GADD153)
Activator protein-1 (AP-1)
Inflammatory
factors
C-reactive protein (CRP)
Cyclooxygenase-2 (COX-2)
Interleukin-1beta (IL-1)
Interleukin-6 (IL-6)
Tumor necrosis factor-alpha (TNF)
Intracellular adhesion molecule-1 (ICAM-1)
Xenobiotic factors Cytochrome P450 1A1 (CYP1A1)
Cytochrome P450 1A2 (CYP1A2)
Cytochrome P450 2B6 (CYP2B6)
Cytochrome P450 2E1 (CYP2E1)
c
c
m
r
7Troponins (C, I, T)
nd integrity of cells and tissues which are typically tissue-
pecific cytoplasmic enzymes that leak from damaged or dying
ells and can be monitored in blood or urine. Usually, a com-
rehensive clinical chemistry profile is performed employing
variety of tissue-specific biomarkers as indicators for organ-
pecific damage such as liver, kidney, brain, heart, vascular
ystem and muscles (Table 1) and (2) biomarkers as indicators
f damage responses of cells and tissues based on the inducible
ellular defense systems. Representative members for the group
f inducible biomarkers such as antioxidant enzymes, antiox-
dants, metal-chelating proteins, repair enzymes, transcription
actors, inflammatory factors or xenobiotic factors are listed in
able 2. Integration of data obtained by these two approaches as
rst line of toxicity assessment is usually validated by histology
hich may potentially lead to causative relationships relevant to
egenerative diseases [3,169–173].
As a result of recent developments in metabolomics the
linical chemistry profile is enhanced by NMR technol-
gy to identify intermediary metabolites associated with a
ariety of pathologies and functional alterations, including
enal and hepatic toxicity [170,171,174]. Furthermore, modern
on-invasive techniques such as positron emission tomogra-
hy (PET), fluorescence magnetic resonance imaging (fMRI),
o
aCytochrome P450 3A4 (CYP3A4)
omputerized tomography (CT), or single-photon emission
omputed tomography (SPECT) are increasingly proposed for
onitoring molecular biomarkers because of possibilities for
elatively direct clinical translation [6,169–171,175–177].
. In silico toxicity modelsThe integration of food toxicology data obtained through-
ut biochemical and cell-based in vitro, animal in vivo
nd human clinical settings enabled the establishment of
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lternative, highly predictable in silico models employing new
ocused cell-based bioassays as valuable tool for toxicity risk
ssessment in food. In silico models are being used to study
athways of subsequent cellular events, starting from a molec-
lar initiating event, through a sequential series of higher order
ffects using complex in vitro cell-based models and com-
uter algorithms [7,33,34,178]. As a basic principle, quantitative
tructure–activity relationships (QSAR) between a chemical
tructure and the biological effects give valuable insights into
he molecular mechanisms of action of toxic substances. The
redictive value of QSARs can be greatly enhanced by quan-
itative in vitro to in vivo extrapolation when toxicokinetic
ata on xenobiotic biotransformation, chemical–chemical inter-
ctions, absorption, distribution, bioavailability, metabolism
nd/or excretion of the substance under study are available
2,7,32,34,172,179,180]. Advances of these in silico tools to
ssess toxicity in food has led to a wealth of mechanistic infor-
ation of adverse effects of food toxicants and a significant
eduction in the number of animals required for toxicologi-
al tests for a new active substance [5–8,27,33]. Therefore, in
ilico models are being increasingly recognized as predictive
ools to analyze hepatotoxicity, cardiotoxicity and nephrotoxi-
ity [9,33,34,39,172,181–183].
.1. High-throughput and high content screening methods
Thanks to significant advances made in biotechnology during
he last two decades the majority of toxicity test systems are now
nalyzed by high-throughput or high content screening technol-
gy [4,5,9,25,27,127]. These newly emerged screening systems
ere originally developed by the pharmaceutical industry to
dentify bioactive compounds from huge corporate compound
ibraries [5,184,185]. Whereas the high-throughput approach
s based on quick screening of the biological activity of
umerous compounds, high-content screening includes the mea-
urement of many parameters in a single cell or tissue setting
4–7,9,186,187]. Most of those systems are strongly driven by
uorescence-based bioassays or biosensor systems employing
mage analysis algorithms. These systems allow multiplexing
uorescent endpoints by the use of robotic based screening
n multiwell plates and automated liquid handling equipment
ettings [4–6,40,188]. Due to the establishment of the different
omics technologies the impact of toxicants on genes, proteins,
r metabolites can be analyzed by toxicogenomics, toxico-
roteomics, or toxicometabolomics, respectively [6,27,35–39].
hereas toxicogenomics and toxicoproteomics are fairly estab-
ished screening methods, toxicometabolomics has started to
e integrated as profiling method in the panels for toxicity
ssessment only in the past few years [6,174]. Now, high-
hroughput and high-content technologies in combination with
omics technologies are routinely used throughout biochemical
nd cell-based in vitro, animal in vivo models as well as clini-
al and pathologic analyses. These new techniques allow very
uick screens of a huge number of compounds to yield impor-
ant mechanistic information on numerous critical cell signaling
athways and cell health parameters with unprecedented quality
nd reproducibility. Former trade-offs of high-throughput and
i
p
i
nn Wellness 5 (2016) 103–115
igh-content technology due to high rates of false-positives as
ell as false-negatives have been recently addressed by the use
f quantitative high-throughput screening [5,189,190].
. Concluding remarks
Overall, the achievements in food toxicology in the last
ecades have been significant gaining a deeper understanding of
he molecular mode of action by which toxic effects are induced.
hese mechanistic insights have helped to identify potential
oxicants thus enhancing food safety. The list of toxicants is
rowing and comprises a heterogeneous groups of simple or
omplex molecules which play different roles in toxicological
athways. In Table 3 representative toxicants derived from dif-
erent sources are listed. Major advances in biotechnology in
he use of high-throughput, high content testing programs, -
mics technologies, computational toxicology, as well as the
stablishment of prediction models focusing on quantitative
tructure–activity relationships (QSAR) have augmented our
nowledge of the molecular mechanisms of how food molecules
ffect targets of key biological pathways thus inducing toxicity.
Mining, integration and correlation analysis of toxicological
ata throughout in vitro biochemical and cell-based models, in
ivo animal as well as clinical settings are leading to a better
redictivity of complex in vitro cell-based models as essential
art of in silico systems. Evaluation of complex data obtained by
igh-throughput and high-content screening technologies utiliz-
ng algorithms-based software is now possible through major
ccomplishments in bioinformatics. Human in silico models
ave the advantage that they do not have issues with interspecies
xtrapolation and complex toxicological end points. These mod-
ls can often be analyzed to yield a few specific pathways in
pecific target organs.
Another positive trend in food toxicology is the increased
sage of alternative lower surrogate animal models such as the
ebrafish (D. rerio), the nematode C. elegans and the fruit fly
D. melagonaster). The discovery of a higher degree of evo-
utionary conservation of homologous genes between humans
nd lower vertebrate or invertebrates than assumed decades ago
as allowed for a decrease of rodent animal models in favor
f alternative animal models for use in food toxicology. The
se of these non-traditional organisms offers advantages in the
bsence of ethical concerns with genetic manipulation, organ
oxicology, as well as providing higher throughput and lower
osts over mammalian models, in particular rodents.
Due to the positive developments in food toxicology assess-
ent in the last two decades, but also because of ethical and
xtrapolability concerns as well as an increase of test candi-
ates, there has been a paradigm shift to reduce animal testing.
y virtue of the establishment of predictive in silico toxicity
ssessment tools the traditional endpoint testing moved toward
mechanism-based approach. Although evaluation of toxicants
hrough complex in vitro human cell-based models embedded
n in silico methods are now being increasingly recognized as
redictive tools, there will be a continuous need for compar-
son with traditional in vivo testing. In particular, testing of
ew food ingredients by rodents or larger vertebrates will be
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Table 3
Toxicants derived from different sources. Representative toxic substances are listed. For reference see: [1–6,8,9,17,19,20,24,28,36,37,52,78,81,94,120,
123,168,196,198,199].
Substance
Naturally occurring toxicants
Mycotoxins Aflatoxins, Citrinin, Ochratoxins, Patulin, Fumonisin, Ergot akaloids, Trichothecenes, Zearalenone
Alkaloids Muscarin, Retronecine, Indicine, Lindelophin, Sarracine, Loline, N-formylloline, Coniine, Lupinine, Sparteine,
Trigonelline, Hydrastine, Lycorine, Protopine, Aconitine, Colchicine, Benzylamine, Solanine, Indolizidine,
Piperidine, Tropane, Taxine
Allergens Gliadin, Gluten, Soy/crustacean/fish/cow-milk and other food-derived proteins
Environmental pollutants
Heavy metals Arsenic, Cadmium, Lead, Mercury, Chromium, Copper, Cobalt, Nickel, Zinc, Antimony
Pesticides and Insecticides Dichlorodiphenyltrichloroethane (DDT), Ethylene dibromide (EDB), 1,3-Dichloropropene (DCP),
1,2-Dibromo-3-chloropropane (DBCP) Lindane, Endosulfan, Chlordane, Atrazine, Parathion, Atrazine,
Simazine, Alachlor, Metolachlor, Trifluralin, Diazinon, Aldrin, Malathion, Aldicarb
Antibiotics Tetracyclines, Sulfonamides, Fluoroquinolones, Cephalosporins, Aminoglycosides, Ansamycins, Carbapenems,
Nitrofurans, Glycopeptide antibiotics, Lincosamides, Macrolides
Hormones Estradiol (natural), Zeranol (synthetic), Progesterone (natural), Progestin melengestrol acetate (synthetic),
Testosterone (natural), Trenbolone acetate (synthetic)
Electromagnetic radiation UV radiations, -rays, X-rays
Chemically formed toxicants
Bisphenols Bisphenol A, Polychlorinated biphenyls (PCBs), Polybrominated biphenyls (PBBs), Polybrominated biphenyl
ethers (PBDEs)
Phthalates Di-n-butyl phthalate (DBP), Diethyl phthalate (DEP), Dimethyl phthalate (DMP), Diisodecyl phthalate (DIDP),
Diisononyl phthalate (DINP), Di-2-ethylhexyl phthalate (DEHP), Benzylbutyl phthalate (BzBP)
Aromatic hydrocarbons Benzo[j]fluoranthene, Benzo(a)pyrene, Polychlorinated naphthalenes
Aromatic amines Benzidine 2-Naphthylamine, 4-Aminobiphenyl, 4,4′-Methylene bis 2-choloroaniline, N-Hydroxyarylamines,
2-Aminofluorene, N-Acetyl-2-aminofluorene
Amides and Furans Acrylamide, p-Hydroxyacetanilide, Furan, 5-Hydroxymethylfurfural (HMF)
Aldehydes Formaldehyde, Acetaldehyde, Propionaldehyde, Benzaldehyde, Acrolein
Dioxins or dioxin-like compounds 1,4-Dioxin, Polychlorinated dibenzodioxins (PCDDs), Polychlorinated dibenzofurans (PCDFs)
Nitrosamines N-Nitrosodimethylamine, N-Nitrosodiethylamine, N-Nitrosoanabasine, N-Nitrosoanatabine,
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romatic nitro compounds Nitrobenzenes, Nitrotoluene
nevitable to identify whole-animal and mechanistic organ level
esponses to integrate new data into in silico software systems.
ecently, organotypic systems and stem cell-based assays are
eing discussed as very promising sources for various toxi-
ological applications. Although still in early development the
ong-term potential for these approaches to predict acute toxicity
s very high. The application of these or other models will help
o further answer fundamental biological questions and pave the
oad toward the goal of higher specificity and accuracy aiming
or a reduction of animal toxicological testing.
Despite the achievements in many areas of food toxicology,
here are numerous challenges in predicting and/or translating
he effects of specific toxicants in food due to: (1) crosstalk of
oxicants by interacting with different endogenous and exoge-
ous molecules (such as drugs and food matrixes) throughout
ifferent toxicity pathways; (2) the fact that toxicity pathways
ill be perturbed differently due to cell-, tissue-, organ- and
ven organisms-type dependent variability in gene expression;
3) the fact that some forms of toxicity are dependent on higher
rder interactions of cells in tissues or organs; (4) the possible
odifications during digestion and absorption; (5) the aspects
f immune sensitization or desensitization; (6) the difference
n solubility, bioavailability, biotransformation and bioconver-
ion; (7) human variability such as heterogeneity, epigenetics,
ender, size, health and age; (8) the impact of toxicants onophenols, Nitronaphthalenes, Nitrobiphenyls
ifferent nutritional health, disease status or other environ-
ental factors; (9) xenometabolisms in the liver and other
rgans; and (10) the lack of standardization in synthesis and
hemical characterization as well as the normalization of test
ompounds.
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